Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report
|Reure J*, Follana P and Ferrero JM|
|Centre Antoine Lacassagne, 33 Avenue Valombrose, 06000 Nice, France|
|Corresponding Author :||Juliette Reure
Centre Antoine Lacassagne, 33 Avenue
Valombrose, 06000 Nice, France
E-mail: [email protected]
|Received March 13, 2015; Accepted April 06, 2015; Published April 14, 2015|
|Citation: Reure J, Follana P, Ferrero JM (2015) Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report Clin Pharmacol Biopharm 4:136. doi:10.4172/2167-065X.1000136|
|Copyright: © 2015 Reure J et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: HER 2 Metastatic Breast Cancer (MBC) is usually considered incurable. Prognosis has considerably improved over the past two decades with the advent of new therapies such as monoclonal antibodies interfering with the Her2/neu receptor.
Case presentation: We present a case of 61 year old woman with Her2 positive MBC without any sign of recurrence 5 years after the end of trastuzumab and who could be potentially considered cured.
Conclusion: In case of sustained response, stopping trastuzumab is possible without recurrence. We can reasonably hope that patients without recurrence after 5 years, as in our case, are definitely cured.